dipyridamole has been researched along with Cancer of Ovary in 9 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dipyridamole (DPM), a nucleoside membrane transport inhibitor, enhanced the cytotoxicity of cisplatin (DDP) for human ovarian carcinoma 2008 cells by a factor of 4." | 7.68 | Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. ( Chan, TC; Howell, SB; Jekunen, A; Sanga, R; Vick, J, 1992) |
| "Dipyridamole (DPM), a nucleoside membrane transport inhibitor, enhanced the cytotoxicity of cisplatin (DDP) for human ovarian carcinoma 2008 cells by a factor of 4." | 3.68 | Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. ( Chan, TC; Howell, SB; Jekunen, A; Sanga, R; Vick, J, 1992) |
| "Among ovarian cancer cell lines tested, the enhancement of the activity of HuIFN by dipyridamole for HAC-2 and SHIN-3 cells was equivalent to or greater than that for 3 chemotherapy agents (adriamycin, vincristine, and a camptothecin derivative)." | 1.28 | Dipyridamole enhances an anti-proliferative effect of interferon in various types of human tumor cells. ( Fukazawa, I; Inaba, N; Isogai, E; Oiwa, Y; Saito-Ebihara, M; Sekiya, S; Sugano, I; Suzuki, N; Takakubo, Y; Yoshida, J, 1992) |
| "Dipyridamole (DP) is an attractive agent with which to increase the selectivity of intraperitoneally delivered methotrexate (MTX)." | 1.28 | Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate. ( Goel, R; Howell, SB; Sanga, R, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barry, CP | 1 |
| Lind, SE | 1 |
| Suzuki, N | 1 |
| Oiwa, Y | 1 |
| Sugano, I | 1 |
| Inaba, N | 1 |
| Sekiya, S | 1 |
| Fukazawa, I | 1 |
| Yoshida, J | 1 |
| Takakubo, Y | 1 |
| Isogai, E | 1 |
| Saito-Ebihara, M | 1 |
| Jekunen, A | 1 |
| Vick, J | 1 |
| Sanga, R | 3 |
| Chan, TC | 3 |
| Howell, SB | 6 |
| Kirmani, S | 1 |
| Goel, R | 2 |
| Hom, D | 1 |
| Vick, JS | 1 |
| Abramson, IS | 1 |
| Mosesson, MW | 1 |
| Colman, RW | 1 |
| Sherry, S | 1 |
9 other studies available for dipyridamole and Cancer of Ovary
| Article | Year |
|---|---|
Adenosine-mediated killing of cultured epithelial cancer cells.
Topics: Adenine; Adenosine; Adenosine Deaminase Inhibitors; Adenosine Kinase; Apoptosis; Breast Neoplasms; C | 2000 |
Dipyridamole enhances an anti-proliferative effect of interferon in various types of human tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cell Div | 1992 |
Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
Topics: Carcinoma; Cell Membrane Permeability; Cisplatin; Dipyridamole; Drug Synergism; Female; Humans; Ovar | 1992 |
Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cyclic AMP; Dipyridamole; Drug Synergism; | 1990 |
Novel approaches to intraperitoneal drug delivery.
Topics: Antineoplastic Agents; Dipyridamole; Dose-Response Relationship, Drug; Drug Evaluation; Drug Synergi | 1989 |
Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate.
Topics: Ascitic Fluid; Cell Line; Dipyridamole; Drug Evaluation, Preclinical; Drug Stability; Drug Synergism | 1989 |
Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole.
Topics: Animals; Cell Line; Cell Survival; Colony-Forming Units Assay; Dipyridamole; Doxorubicin; Drug Syner | 1989 |
Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cell Line; Dip | 1985 |
Chronic intravascular coagulation syndrome.
Topics: Beta-Globulins; Blood Cell Count; Blood Coagulation Disorders; Blood Coagulation Tests; Blood Platel | 1968 |